(19)
(11) EP 1 541 197 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.06.2009 Bulletin 2009/24

(45) Mention of the grant of the patent:
18.03.2009 Bulletin 2009/12

(21) Application number: 04025035.9

(22) Date of filing: 21.10.2004
(51) International Patent Classification (IPC): 
A61K 31/343(2006.01)
A61P 25/22(2006.01)
 A61K 31/4545(2006.01)
A61P 25/24(2006.01)

(54)

Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders

Verwendung von Pipamperon und einem SNDRI, SNRI oder SSRI zur Behandlung von Stimmungs- oder Angststörungen

Utilisation de pipamperone et d'un SNDRI, SNRI ou SSRI pour le traitement des troubles de l'humeur ou anxieux

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 02.12.2003 EP 03447279
05.01.2004 EP 04447001
18.03.2004 EP 04447066

(43) Date of publication of application:
15.06.2005 Bulletin 2005/24

(73) Proprietor: PharmaNeuroBoost N.V.
3570 Alken (BE)

(72) Inventor:
  • Buntinx, Erik
    3750 Alken (BE)

(74) Representative: De Clercq, Ann G. Y. et al
De Clercq, Brants & Partners c.v. Edgard Gevaertdreef 10a
9830 Sint-Martens-Latem
9830 Sint-Martens-Latem (BE)


(56) References cited: : 
WO-A-98/43646
US-A- 5 762 960
 DE-A- 4 039 631
   
  • VOLMAT R ET AL: "The treatment of depressions by Cledial. Evolution and clinical state and handwriting" PSYCHOLOGIE MEDICALE 1986 FRANCE, vol. 18, no. 10, 1986, pages 1615-1622, XP009028776
  • SQUELART P ET AL: "Pipamperone (Dipiperon), a useful sedative neuroleptic drug in troublesome chronic psychotic patients." ACTA PSYCHIATRICA BELGICA. BELGIUM 1977 MAR-APR, vol. 77, no. 2, March 1977 (1977-03), pages 284-293, XP009028314 ISSN: 0300-8967
  • KOCH H J ET AL: "Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride." INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. ENGLAND MAR 2003, vol. 57, no. 2, March 2003 (2003-03), pages 147-149, XP009030046 ISSN: 1368-5031
  • DIEBOLD K. ET AL: "Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?." PHARMACOPSYCHIATRY, (1998) 31/2 (60-67)., 1998, XP009029360
  • PERUGI G ET AL: "EFFECTIVENESS OF ADJUNCTIVE GABAPENTIN IN RESISTANT BIPOLAR DISORDER: IS IT DUE TO ANXIOUS-ALCOHOL ABUSE COMORBIDITY?" JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, WILLIAMS AND WILKINS, US, vol. 22, no. 6, 2002, pages 584-591, XP009029358 ISSN: 0271-0749
  • ADLER L ET AL: "PRAXIS DER STATIONAEREN AKUTBEHANDLUNG VON MANIEN RETROSPEKTIVE VERGLEICHSUNTERSUCHUNG AN JE 100 PATIENTEN ZWEIER PSYCHIATRISCHER ZENTREN PRACTICE OF IN-PATIENT ACUTE TREATMENT OF MANIAS" FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, STUTTGART, DE, vol. 62, no. 12, 1994, pages 479-488, XP009029389 ISSN: 0720-4299
  • ANSOMS C ET AL: "Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamperone (Dipiperon)." ACTA PSYCHIATRICA SCANDINAVICA. FEB 1977, vol. 55, no. 2, February 1977 (1977-02), pages 116-122, XP009041169 ISSN: 0001-690X
  • LEYSEN J E ET AL: "RECEPTOR INTERACTI0NS OF NEW ANTIPSYCHOTICS: RELATION TO PHARMACODYNAMIC AND CLINICAL EFFECTS" INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, MARTIN DUNITZ, LONDON, GB, vol. 2, no. 1, 1998, pages S03-S17, XP001009585 ISSN: 1365-1501
  • DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, SCHOTTE A ET AL: "Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding" XP002290498 Database accession no. PREV199698829913 & PSYCHOPHARMACOLOGY, vol. 124, no. 1-2, 1996, pages 57-73, ISSN: 0033-3158
  • VANHOENACKER P ET AL: "EFFICIENT EXPRESSION OF THE HUMAN DOPAMINE D4.2 RECEPTOR: POSITIVE INFLUENCE OF PIPAMPERONE ON EXPRESSION LEVELS" ABSTRACTS OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 26, no. 1/2, 2000, page 1, XP001181469 ISSN: 0190-5295
  • VIJVER VAN DE D A M C ET AL: "ANTIPSYCHOTICS AND PARKINSON'S DISEASE: ASSOCIATION WITH DISEASE AND DRUG CHOICE DURING THE FIRST 5 YEARS OF ANTIPARKINSONIAN DRUG TREATMENT" EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, SPRINGER VERLAG, DE, vol. 58, no. 7, 2002, pages 157-161, XP009033980 ISSN: 0031-6970
  • ENGELBORGHS S ET AL: "AMINO ACIDS AND BIOGENIC AMINES IN CEREBROSPINAL FLUID OF PATIENTS WITH PARKINSON'S DISEASE" NEUROCHEMICAL RESEARCH, PLENUM PRESS, NEW YORK, US, vol. 28, no. 8, August 2003 (2003-08), pages 1145-1150, XP009031514 ISSN: 0364-3190
  • DATABASE EMBASE [Online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1999, ETCHEPAREBORDA M C: "Neurocognitive and pharmacological approach to specific learning disorders" XP002312308 Database accession no. EMB-2000050033 & REVISTA DE NEUROLOGIA 1999 SPAIN, vol. 28, no. SUPPL. 2, 1999, pages S81-S93, ISSN: 0210-0010
  • WIRZ-JUSTICE A ET AL: "HALOPERIDOL DISRUPTS, CLOZAPINE REINSTATES THE CIRCADIAN REST-ACTIVITY CYCLE IN A PATIENT WITH EARLY-ONSET ALZHEIMER DISEASE" ALZHEIMER DISEASE AND ASSOCIATED DISORDERS, RAVEN PRESS, NEW YORK, NY, US, vol. 14, no. 4, 2000, pages 212-215, XP009029353 ISSN: 0893-0341
  • FAHS H ET AL: "THYMOREGULATEURS DANS L'AGITATION ET LES TROUBLES DU COMPORTEMENT CHEZ LE SUJET DEMENT A PROPOS DE HUIT CAS ANTICONVULSIVANTS AND AGGRESSIVE BEHAVIORS IN ALZHEIMER'S DISEASE. EIGHT CASES REPORTS" ENCEPHALE, PARIS, FR, vol. 25, no. 2, 1999, pages 169-174, XP009039295 ISSN: 0013-7006
  • GRÖZINGER M ET AL: "Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine." PHARMACOPSYCHIATRY. GERMANY JAN 2003, vol. 36, no. 1, January 2003 (2003-01), pages 3-6, XP009029363 ISSN: 0176-3679
  • WERTH ESTHER ET AL: "Decline in long-term circadian rest-activity cycle organization in a patient with dementia." JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY. 2002 SPRING, vol. 15, no. 1, April 2002 (2002-04), pages 55-59, XP009042127 ISSN: 0891-9887
  • STAHL STEPHEN M ET AL: "Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease." CURRENT MEDICAL RESEARCH AND OPINION. APR 2004, vol. 20, no. 4, April 2004 (2004-04), pages 517-524, XP009041652 ISSN: 0300-7995
  • DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, MELTZER HERBERT Y ET AL: "Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine" XP002290499 Database accession no. PREV199598192811 & NEUROPSYCHOPHARMACOLOGY, vol. 12, no. 1, 1995, pages 39-45, ISSN: 0893-133X
  • MUENCHAU A ET AL: "PHARMACOLOGICAL TREATMENT OF PARKINSON'S DISEASE" POSTGRADUATE MEDICAL JOURNAL, MCMILLAN PRESS, BASINGSTOKE, GB, vol. 76, no. 900, October 2000 (2000-10), pages 602-610, XP009034316 ISSN: 0032-5473
  • FALTRACO F ET AL: "AKTUELLE THERAPIEMOEGLICHKEITEN DER ALZHEIMER DEMENZ CURRENT THERAPEUTICAL STRATEGIES IN DEMENTIA" NEUROLOGIE UND REHABILITATION, BONN, DE, vol. 9, no. 1, 2003, pages 15-22, XP009041267 ISSN: 0947-2177
  • MONTGOMERY S.A.; ANDERSEN H.F.: 'Escitalopram versus venlafaxine XR in the treatment of depression' INTERNATIONAL CLINICAL PHARMACOLOGY vol. 21, no. 5, 2006, pages 297 - 309
  • KHAN ARIF; WARNER HEATHER A.; BROWN WALTER A.: 'Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database' ARCHIVES OF GENERAL PSYCHIATRY vol. 57, no. 4, 2000, pages 311 - 317
  • MOORE NICHOLAS; VERDOUX HÉLÈNE; FANTINO BRUNO: 'Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder' INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY vol. 20, no. 3, 2005, pages 131 - 137
  • WIELING W. ET AL: 'INITIAL ORTHOSTATIC HYPOTENSION AS A CAUSE OF RECURRENT SYNCOPE: A CASE REPORT' CLINICAL AUTONOMIC RESEARCH vol. 11, no. 4, 2001, page 270, XP009039296
  • FOUKS D. ET AL: 'TRAITEMENT DES TROUBLES CARACTERIELS PAR UNE NOUVELLE BUTYROPHENOME: LE R. 3345 OU PIPAMPERONE//TREATMENT OF CHARACTER DISORDERS WITH A NEW BUTYROPHENONE: R. 3345 OR PIPAMPERONE' ANNALES MEDICO-PSYCHOLOGIQUES vol. 124, no. 5, 1966, pages 677 - 681, XP009028328
  • "Pipamperone dichlorhydrate"[Online] 2000, pages 1-4, Retrieved from the Internet: URL:http://www.biam2.org/www/Sub2783.html> [retrieved on 2007]
  • 'Médicaments psychotropes: posologies chez l'enfant et l'adolescent', [Online] 2001, pages 1 - 3 Retrieved from the Internet: <URL:http://www.adiph.org/pic/pedia-neurole ptiques.pdf> [retrieved on 2007-00-00]
  • HEISER P.; REMSCHMIDT H.: 'SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND NEWER ANTIDEPRESSIVE SUBSTANCES IN CHILD AND ADOLESCENT PSYCHIATRY. DIE SELEKTIVEN SEROTONIN-WIEDERAUFNAHMEHEMMER UND DIE NEUEREN ANTIDEPRESSIVA-SUBSTANZEN IN DER KINDER- UND JUGENDPSYCHIATRIE' ZEITSCHRIFT FUER KINDER- UND JUGENDPSYCHIATRIE UNDPSYCHOTHERAPIE vol. 30, no. 3, 2002, pages 173 - 183, XP009076880
  • CARLIER P.R. ET AL: 'Synthesis of a Potent Wide-Spectrum Serotonin-, Norepinephrine-, Dopamine-Reuptake Inhibitor (SNDRI) and a Species-Selective Dopamine-Reuptake Inhibitor Based on the Gamma-Amino Alcohol Functional Group' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 8, no. 5, 1998, pages 487 - 492
  • MAINA GIUSEPPE ET AL: 'ANTIPSYCHOTIC AUGMENTATION FOR TREATMENT RESISTANT OBSESSIVE-COMPULSIVE DISORDER: WHAT IF ANTIPSYCHOTIC IS DISCONTINUED?' INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY vol. 18, no. 1, 01 January 2003, pages 23 - 28, XP009078546
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).